Immuneering Corporation Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Immuneering Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $24.61K, a 1097.47% increase year-over-year.
- Immuneering Corporation stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $10.44K.
- Immuneering Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $136.65K.
- Immuneering Corporation stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $2.06K.
- Immuneering Corporation stock issued during period, value, stock options exercised for fiscal 2025 was $368.53K, a 49.69% decline from fiscal 2024.
- Immuneering Corporation stock issued during period, value, stock options exercised for fiscal 2024 was $732.46K, a 64.66% increase from fiscal 2023.
- Immuneering Corporation stock issued during period, value, stock options exercised for fiscal 2023 was $444.84K, a 48.09% increase from fiscal 2022.
- Immuneering Corporation stock issued during period, value, stock options exercised for fiscal 2022 was $300.38K, a 15.25% decline from fiscal 2021.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $24.61K 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $10.44K 10-Q · filed 2026-08-05 | |
| 2025-12-31 | $368.53K 10-K · filed 2026-03-06 | |
| 2025-09-30 | $136.65K 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $2.06K 10-Q · filed 2026-08-05 | |
| 2024-12-31 | $732.46K 10-K · filed 2026-03-06 | |
| 2024-03-31 | $732.46K 10-Q · filed 2025-11-12 | |
| 2023-12-31 | $444.84K 10-K · filed 2025-03-20 | |
| 2023-09-30 | $21.45K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $176.15K 10-Q · filed 2024-11-13 | |
| 2023-03-31 | $239.41K 10-Q · filed 2024-11-13 | |
| 2022-12-31 | $300.38K 10-K · filed 2024-03-01 | |
| 2022-09-30 | $37.39K 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $27.78K 10-Q · filed 2023-11-09 | |
| 2022-03-31 | $193.11K 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $354.43K 10-K · filed 2023-03-06 | |
| 2021-09-30 | $294.29K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $52.63K 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Coya Therapeutics, Inc. (COYA) | United States | $0.121B | -6.35 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |